Metabolic acidosis commonly complicates chronic kidney disease (CKD) and has adverse eff ects on bone, nutrition, and metabolism. For patients treated with dialysis, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend maintaining serum bicarbonate levels у 22 m M to help prevent these complications. 1 Phisitkul et al. 2 (this issue) now demonstrate that sodium citrate (as an alkalinizing agent) may ameliorate kidney injury in CKD patients not on dialysis. Further, they provide evidence in humans that bicarbonate lowers urinary endothelin levels, and hence increased endothelin may be part of the mechanism whereby acidosis hastens CKD progression.
Metabolic acidosis is a predictable accompaniment of CKD. 3 Adaptations in kidney acid excretion may initially prevent a fall in serum bicarbonate levels, but as glomerular fi ltration rate (GFR) declines to the 20-to 40-ml / min range, metabolic acidosis commonly develops. Initially this acidosis is typically a hyperchloremic variety, but in later stages of CKD it may be a highanion-gap acidosis. Hydrogen ion excretion is relatively intact, so urine pH generally remains appropriately low.
When factored for GFR, titratable acid excretion is augmented. However, the ability to excrete more phosphate during acidosis is limited, so adaptation in titratable acidic excretion is limited. As in all metabolic acidoses, the major adaptation to net urinary acid excretion is an increase in ammonium excretion. In metabolic acidosis, ammonium excretion may increase manyfold; in CKD, when factored for GFR, ammonium excretion is augmented. However, even when factored for GFR, ammonium excretion in CKD is lower than is seen in metabolic acidosis of other etiologies. In absolute terms, total urinary ammonium excretion is markedly impaired. Several mechanisms contribute to the failure of ammonium excretion to keep pace with the decline in GFR. Proximal tubule ammoniagenesis is increased but may be insufficient because of a decline in total nephron mass and possibly because of a defect in glutamine uptake (the major source of renal ammonium). Furthermore, ammonium produced in the proximal tubule may not be transported into the collecting duct, predominantly because of a decrease in interstitial ammonium concentration (see below). Whether other mechanisms exist to limit ammonium excretion is unknown, but some data suggest that the specifi c ammonia transporter Rhcg does increase in the 5 / 6 nephrectomy model of reduced renal mass. 4 A few previous studies have suggested that alkali therapy slows progression of CKD. In 1985, Nath et al. reported that correction of metabolic acidosis in the rat remnant kidney model ameliorates the decline in renal function. 5 Tubulointerstitial injury is a powerful predictor of progression in kidney failure, and the study by Nath et al. showed that bicarbonate treatment led to less severe interstitial injury and higher GFRs. Nath et al. presented data in support of the postulation that increased ammonia levels in the kidney led to increased complement cleavage, which in turn mediated tubulointerstitial injury. Although complement cleavage may well play an important role in progression of kidney failure, it was not convincingly shown to be paramount. Notably, in the same rat remnant kidney model, ammonia levels in the cortex are about twice those of controls, but levels in the medulla are actually lower. 6 Also, some subsequent experimental studies failed to support the benefi cial eff ects of alkali on progression of renal disease.
In more recent years, our understanding of the mechanisms of progression of CKD has markedly expanded. However, few laboratories have addressed how bicarbonate might ameliorate CKD progression. But Wesson ' s group has explored the effects of acidosis on endothelin and the subsequent effects on kidney injury. 7 -9 Studies in rats showed that dietary protein via acid production induces endothelin production. 8 Endothelin stimulated collecting duct acid secretion via endothelin B receptors and tubulointerstitial injury via endothelin A receptors 7, 8 ( Figure 1 ). Bicarbonate ameliorated the injury induced by protein. 7 Wesson ' s group further showed that dietary protein induced a lower cortical interstitial pH and, by manipulating the diet, showed that injury correlated with pH. 9 Other laboratories have demonstrated that endothelin mediates in part the response of the proximal tubule to acidosis (see, for example, Laghmani et al. 10 ). Clinical studies examining the mechanisms of the eff ects of correction of acidosis have been even more limited. Th us, the observation by Phisitkul et al. 2 (this issue) that sodium citrate may exert a beneficial effect on endothelinmediated progression is important. Metabolic acidosis often complicates chronic kidney disease (CKD) and adversely affects bone, nutrition, and metabolism. Phisitkul et al. demonstrate that sodium citrate may ameliorate kidney injury in CKD patients not on dialysis. Further, they provide evidence in humans that treatment lowers urinary endothelin levels, and hence increased endothelin may be part of the mechanism whereby acidosis hastens CKD progression.
D -glucosaminidase, a marker of tubulointerstitial injury, urinary albumin, and urinary transforming growth factor-1. Additional eff ects of bicarbonate or citrate may yet be identifi ed.
The study by Phisitkul et al. 2 also shows that over a 2-year period, treatment with sodium citrate (equivalent to sodium bicarbonate but more palatable) slowed progression of CKD to severe CKD. (Th e eff ects on serum creatinine and estimated GFR were not statistically signifi cant with citrate therapy, but other measures of kidney disease progression were signifi cant.) Th is study addressed only patients with CKD presumably secondary to hypertension. A similar recent study in a larger group of patients with more varied etiology and more severe initial disease by de Brito-Ashurst et al. 11 showed a benefi cial eff ect of sodium bicarbonate on progression of CKD. Th e latter study also showed a benefi cial eff ect of sodium bicarbonate on nutritional parameters. Both recent clinical studies were remarkably similar in the eff ects of alkali treatment on progression of CKD. In both studies there was a group of control patients, representing 25 -45 % of the controls, who had a dramatic decline in kidney function over 12 -30 months. In both studies, bicarbonate treatment decreased this number by about 80 % . Th us, this simple maneuver had powerful eff ects particularly in a subset of patients.
A potential concern regarding treatment of patients with CKD with sodium bicarbonate or sodium citrate is the possible increase in extracellular fl uid volume and hypertension. Such concerns were addressed more than 30 years ago by Husted et al. 12 Th ey examined patients with advanced CKD with average GFRs of about 10 ml / min. Patients were placed on an extremely low-sodium diet of 10 mequiv. per day and supplemented with either sodium chloride or sodium bicarbonate. Sodium chloride but not sodium bicarbonate produced an increase in weight and blood pressure. Th e two recent clinical studies 2, 11 suggest that sodium bicarbonate or citrate supplementation is indeed safe even when added to a more normal-sodium diet; blood pressures, clinical edema, and heart failure were not worsened by sodium alkali supplementation. Th e amount of sodium citrate prescribed in the study by Phisitkul et al. 2 was 1 mequiv. / kg / d. Th is amount of bicarbonate would be suffi cient to neutralize the entire acid load present in the usual Western diet. It seems likely that the amount of citrate ingested was less than prescribed (as judged by the reduction in net acid excretion). Th e amount of sodium bicarbonate used by Brito-Ashurst et al. 11 was 1800 mg in divided doses (about 21 mequiv.), titrated up as needed to normalize plasma bicarbonate; the amount actually used averaged 1820 mg / d. Thus, it appears that relatively modest doses of alkali are suffi cient to exert a benefi cial eff ect. Th eoretical concerns about possible detrimental eff ects of alkali on calcium phosphate deposition in the kidney have not been borne out in these clinical studies. Another theoretical aspect that may not be clinically signifi cant, and which could be addressed in future studies, is that citrate (and not bicarbonate) has been shown to increase aluminum absorption in the gastrointestinal tract. 13 Th us, alkali supplementation as bicarbonate or citrate appears to be a promising and inexpensive approach to retarding progression of renal insufficiency and improving nutritional status. Several unanswered questions remain. Will the results hold up to larger blinded studies in patients with diverse causes of kidney disease? What is the level of acidosis or plasma bicarbonate that warrants treatment? If patients are not acidotic, will sodium bicarbonate or citrate be eff ective and safe? What amount of sodium bicarbonate is actually needed to see the benefi cial eff ect? Finally, further studies on mechanisms are needed. In the era of cost -benefi t analysis, alkali supplementation appears to be a promising low-cost, high-benefit adjunct treatment for patients with CKD.
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Figure 1 | Mechanisms linking acidosis and CKD.
CKD leads to metabolic acidosis, which may promote interstitial fibrosis due to adaptations in ammonia handling. Additionally, the acidic milieu may stimulate endothelin (ET) production, which may promote interstitial fibrosis. However, endothelin may have a salutatory effect of promoting acid secretion, which would ameliorate the acidosis (X). Bicarbonate therapy would directly ameliorate the acidosis (X). ETA, endothelin A; ETB, endothelin B. It is certain that a higher serum uric acid level increases the risk of gout. Many dietary factors raise the serum uric acid level, such as alcohol, seafood, and meat, whereas dairy intake reduces it. Th ere is now substantial evidence that higher fructose intake also increases the serum uric acid level and increases the risk of gout. 1,2 However, it is unclear whether fructose, the predominant sweetener in sugar-sweetened beverages such as sodas, has other important health consequences.
Much of the debate around the role of fructose involves the potential impact of serum uric acid on blood pressure. A higher serum uric acid level is associated with an increased risk of hypertension in younger individuals, but it is unclear whether the uric acid is causal or simply a marker. Th ere are persuasive animal data about the potential harmful eff ect of uric acid on vascular function and blood pressure, but the importance in humans remains to be determined. In fact, several lines of evidence suggest that uric acid may be only a marker for hypertension risk in humans. For example, reducing uric acid levels in humans either with recombinant uricase or with probenecid does not improve vascular function, in contrast to animal studies. 3, 4 Furthermore, the prospective association between fructose Sugar-sweetened beverages and chronic disease Gary C. Curhan 1 and John P. Forman 1 Sugar-sweetened beverages, a major source of fructose, raise serum uric acid levels and are associated with an increased risk of gout, hypertension, and diabetes. However, it is unclear whether the associations with hypertension and diabetes are caused by fructose per se, or through some other mechanism. Nevertheless, given their demonstrated adverse health associations and the lack of any health benefit, the evidence favors minimization of sugar-sweetened beverage intake. intake and gout and that between fructose intake and hypertension are greatly dissimilar ( Figure 1 ) . Th is was demonstrated by the strong association between fructose intake and risk of gout in a large male cohort. However, a prospective study in this same male cohort and two large female cohorts, involving more than 200,000 individuals and over 57,000 incident cases of hypertension, found no association between fructose intake and risk of incident hypertension. 5 In addition, a significant ass o ciation b e t we e n s o d a consumption and hypertension was found for both sugar-sweetened and artifi cially sweetened beverages, 6 suggesting a mechanism not related to the sweetener. Th us, at present, it does not seem likely that fructose intake infl uences the risk of hypertension in humans.
The inverse cross-sectional relation between serum uric acid and renal function has been known for decades, but recent studies also suggest that higher uric acid levels may predict the subsequent loss of renal function, though not necessarily with chronic kidney disease. 7 Although animal data suggest a potential causal relation, the human data to date support only a possible association.
Bomback and colleagues 8 (this issue) now report on a study examining the relation between sugar-sweetened soda consumption and hyperuricemia and chronic kidney disease (CKD). Th ey believed that hyperuricemia was ' a causal intermediate in the association of sugar-sweetened soda consumption and CKD, ' so they analyzed these outcomes separately. Th ey used the well-known and high-quality Atherosclerosis Risk in Communities study (ARIC), involving more than 15,000 white and black adults in the United States. As expected, the baseline cross-sectional study found that individuals with higher sugar-sweetened soda consumption were signifi cantly more likely to meet the criteria for hyperuricemia. Th e fi ndings are consistent with previous reports, including those from the National Health and Nutrition Examination Survey (NHANES). 2 Bomback et al. 8 also found a marginal association between higher soda consumption and prevalent CKD (estimated glomerular fi ltration rate < 60 ml / min per 1.73 m 2 ). However, in the longitudinal
